patent/KR-20060113729-A

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20060113729-A

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-12
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
filingDate	2004-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1e9078a30d1e5c0ccf05ea611776a71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d54055ed35e81af396496644693ab7f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34af450328dd7d686e4081d0dab88740 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82c7c3a77f02f6149abe44a9ed656298 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_062be24ce35535b975ba9d8bd1a8addd
publicationDate	2006-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	KR-20060113729-A
titleOfInvention	Prolinylarylacetamide
abstract	The present invention is a novel compound of formula (I):n n n [Formula I]n n n n n n n n (Wherein,n n n R, R 1 , R 2 , R 3 , X, X 'and Y have the meaning recited in claim 1)n n n It is about. The compound is an inhibitor of coagulation factor Xa and can be used for the prevention and / or treatment of thromboembolic diseases and for the treatment of tumors.
priorityDate	2003-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457189875 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467082926

Total number of triples: 31.